| abstract |
The present invention provides an antigen binding protein that specifically binds TNF-alpha. For example, new variants of anti-TNF antibodies, such as adalimumab, which exhibit increased binding or increased half-life to the FcRn receptor relative to adalimumab, are provided. Compositions comprising antigen binding proteins in the treatment of disorders and or diseases and uses of such compositions are also provided. |